ReviewPleura and peritoneum2017
Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice.
Review in Pleura and peritoneum, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Suspended Microbubbles With Ultrasound Visualization and Sustained Drug Release Properties for Enhancing Intraperitoneal Perfusion Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- The Effect of Splenectomy on Postoperative Morbidity and Survival in Patients with Peritoneal Carcinomatosis.Journal of clinical medicine · 2025Article
- Gastric cancer with limited peritoneal metastasis: Role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Appendiceal mucinous neoplasms: Optimizing treatment strategies based on clinical, histological, and molecular features.World journal of clinical oncology · 2025Review
- Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives.Cancers · 2025Review
- Plasma-activated media selectively induces apoptotic death via an orchestrated oxidative stress pathway in high-grade serous ovarian cancer cells.Molecular oncology · 2025Article
- Current Status of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer (CRC).South Asian journal of cancer · 2024Review
- Long-Term Outcomes following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin.Current oncology (Toronto, Ont.) · 2024Article
- Outcomes of minimal access cytoreductive surgery (M-CRS) and HIPEC/EPIC vs. open cytoreductive surgery (O-CRS) and HIPEC/EPIC in patients with peritoneal surface malignancies: a meta-analysis.Pleura and peritoneum · 2024Review
- 2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma.Annals of surgical oncology · 2023Article
- Treating colorectal peritoneal metastases with an injectable cytostatic loaded supramolecular hydrogel in a rodent animal model.Clinical & experimental metastasis · 2023Article
- Role of Hyperthermic Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery as Consolidation Therapy for Advanced Epithelial Ovarian Cancer.Annals of surgical oncology · 2023Article
- Appendiceal Goblet Cell Carcinoma: Role of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).Indian journal of surgical oncology · 2023Review
- Review
- Advances in the management of peritoneal malignancies.Nature reviews. Clinical oncology · 2022Review
- Malignant peritoneal mesothelioma literature review: past, present, and future.Digestive medicine research · 2022Article
- Primary and metastatic peritoneal surface malignancies.Nature reviews. Disease primers · 2021Review
- Influence of pre-analytical sample preparation on drug concentration measurements in peritoneal tissue: anPleura and peritoneum · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are still lacking a much-needed standardization among the various IP chemotherapy treatment modalities used today in clinical practice. Pharmacologic evidence should be generated to answer important questions raised by the myriad of variables associated with IP chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.